Results of 6 month short course chemotherapy for pulmonary tubercul-osis with 2SHRZ/4HR.

Lee, Hyong Ju; Min, Chul Hong; Lee, Sun Woo; Park, In Won; Choi, Byoung Whui; Hue, Sung Ho

doi:1991.38.2.93

Tuberc Respir Dis > Volume 38(2); 1991 > Article

Original Article

Tuberculosis and Respiratory Diseases 1991;38(2):93-98.
DOI: https://doi.org/10.4046/trd.1991.38.2.93 Published online June 1, 1991.

Results of 6 month short course chemotherapy for pulmonary tubercul-osis with 2SHRZ/4HR.

Hyong Ju Lee, Chul Hong Min, Sun Woo Lee, In Won Park, Byoung Whui Choi, Sung Ho Hue

Department of Internal Medicine, College of Medicine Chung-Ang University, Seoul, Korea

Abstract

A clinical trial was made on 76 patients with pulmonary tuberculosis to determine the effectiveness and acceptability of 6 month 2SHRZ/ 4HR antituberculosis regimen. Out of 76 patients, 13 patients (1 7.1 %) dropped out and 11 patients (14 .5%) were excluded due to drug resistance. In 3 patients (3.9%), regimen was changed due to adverse effects. Treatment failure rate was 2.0% in 50 patients. One patient, who had far advanced lesion, was treated longer than 6 months due to failure of sputum conversion. The most common adverse effect was arthralgia, which was controlled by the administration of allopurinol and nonsteroidal anti-inflammatory drug. In conclusion, 2SHRZ/ 4HR for 6 months was effective regimen in treating the newly-diagnosed patients with tuberculosis, but change of the regimen and duration might be carefully considered by the severity of the lesion and adverse effect of the drug But further study will be needed to evaluate not only the efficacy and efficiency of 6 month chemotherapy but also relapse rates.